PUMA BIOTECHNOLOGY, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $228.4 | $230.5 | $235.6 | $228.0 | $253.2 |
| Operating income | $37.3 | $31.0 | $32.6 | $23.7 | $1.3 |
| Net income | $31.1 | $30.3 | $21.6 | $<0.1 | -$29.1 |
| Balance Sheet | |||||
| Total debt | $102.0 | $102.0 | $102.0 | $102.0 | $102.0 |
| Cash Flow Statement | |||||
| Free cash flow | $41.7 | $38.9 | $26.9 | -$15.8 | $20.6 |
Shares outstanding 50.9M · Free float 83.3%
Annual filing data through FY ended December 31, 2025; float as of August 26, 2026.